See all stories BY BETTINA HAMELIN, HENRY SKINNER
Get The Foreign Policy Newsletter
The key issues and people influencing Canadian foreign policy and diplomacy. Thursday.
By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy
FOLLOW THE HILL TIMES:
Want to make sure your whole office has the full Hill Times experience?
We have team plans available for companies, organizations, classes, Parliament Hill offices and more. Fill out this form and find out if your team is eligible for a discount.
More Opinion
Related Stories
- Developers bring new drugs to Canada later than in other nations. Some aren’t launched here at all. The result is that Canadians who need new drugs either have their access long delayed, or denied.
- Developers bring new drugs to Canada later than in other nations. Some aren’t launched here at all. The result is that Canadians who need new drugs either have their access long delayed, or denied.
- Canada could transform from global laggard to a global leader in the fight against antimicrobial resistance.
- Canada could transform from global laggard to a global leader in the fight against antimicrobial resistance.
- With continued support, HDTs have the potential to become an important tool in both pandemic preparedness and biodefence for Canada and our global partners.
- With continued support, HDTs have the potential to become an important tool in both pandemic preparedness and biodefence for Canada and our global partners.
- The partnership between the WHO and Firstline—an intergovernmental agency and a private firm—is a blueprint for leveraging global expertise and technology to tackle grand-scale health challenges.
- The partnership between the WHO and Firstline—an intergovernmental agency and a private firm—is a blueprint for leveraging global expertise and technology to tackle grand-scale health challenges.
- While patients would undoubtedly like lower drug prices, they don’t want PMPRB actions to lead to developers deciding not to launch new medicines in Canada.
- While patients would undoubtedly like lower drug prices, they don’t want PMPRB actions to lead to developers deciding not to launch new medicines in Canada.
- Politics
- Foreign Policy
- Lobbying
- Legislation
- Policy Briefings
- Politics This Morning
- Hill Climbers
- Civil Circles
- Heard On The Hill
- Election
- Finance and Budget
- Public Service
- Exclusive Lists
- Parliamentary Calendar
- Top 100 Lists and Exclusive Features
- Podcasts
- This Week's Paper
- Search
- Archives
- Digital Newspaper Archives
- Politics
- Foreign Policy
- Lobbying
- Legislation
- Policy Briefings
- Politics This Morning
- Hill Climbers
- Civil Circles
- Heard On The Hill
- Election
- Finance and Budget
- Public Service
- Exclusive Lists
- Parliamentary Calendar
- Top 100 Lists and Exclusive Features
- Podcasts
- This Week's Paper
- Search
- Archives
- Digital Newspaper Archives
-
Get free news updates